Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Source: SeekingAlpha
2026-02-03 08:52:33 ET
Xeris Pharmaceuticals' ( XERS ) shares have surged nearly 100% year-over-year (YoY) as a result of both strong and accelerating commercial revenue growth, improving operational discipline, and positive results from its pipeline. Today, Xeris represents more than just a development-stage biotechnology company; it has transformed into a commercial specialty pharmaceutical business with several successful products and a clear pathway to further growth....
Read the full article on Seeking Alpha
For further details see:
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Xeris Pharmaceuticals Inc.
NASDAQ: XERS
XERS Trading
0.61% G/L:
$5.74 Last:
556,933 Volume:
$5.73 Open:
XERS Latest News
XERS Stock Data
$1,185,529,045
155,188,988
4.48%
76
N/A
Biotechnology & Life Sciences
Healthcare
US
Chicago
